Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflation soared 20%... Which could be the final blow for the American Dream - even with Trump in office.

Take these three steps today to protect your retirement from Biden's legacy >>>

John Shulman Biography and Net Worth

Director of Petros Pharmaceuticals

Mr. Shulman founded Juggernaut in 2009 and leads its Investment Committee. He has over 25 years of experience with private investments, primarily into the consumer, pharmaceutical and business services sectors. Previously, Mr. Shulman was a Managing Director from 2001 to 2009 at Allied Capital Corporation, where he was a member of the Management and Investment Committees. He sits on the following Boards of Directors or Managers: Amerex Group, Ceuta Group, Foundation Consumer Brands, Foundation Consumer Healthcare, Integrated Beverage Group, Petros Pharmaceuticals, Puori ApS, VOSS of Norway AS, and ZOA Energy, LLC.

How old is John D. Shulman?: Mr. Shulman is currently 61 years old. There are 2 older executives and no younger executives at Petros Pharmaceuticals. Learn More on John D. Shulman's age.
How do I contact John D. Shulman?: The corporate mailing address for Mr. Shulman and other Petros Pharmaceuticals executives is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. Petros Pharmaceuticals can also be reached via phone at 973-242-0005 and via email at [email protected]. Learn More on John D. Shulman's contact information.
Has John D. Shulman been buying or selling shares of Petros Pharmaceuticals?: John D. Shulman has not been actively trading shares of Petros Pharmaceuticals within the last three months. Most recently, on Monday, November 29th, John D. Shulman bought 50,000 shares of Petros Pharmaceuticals stock. The stock was acquired at an average cost of $30.00 per share, with a total value of $1,500,000.00. Learn More on John D. Shulman's trading history.

John D. Shulman Insider Trading History at Petros Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/29/2021	Buy	50,000	$30.00	$1,500,000.00
10/18/2021	Buy	166,180	$17.20	$2,858,296.00

John D. Shulman Buying and Selling Activity at Petros Pharmaceuticals

Petros Pharmaceuticals Company Overview

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Today's Range

Now: $0.25

$0.23

$0.27

50 Day Range

MA: $0.34

$0.25

$0.42

2 Week Range

Now: $0.25

$0.22

$2.27

Volume

226,844 shs

Average Volume

519,343 shs

Market Capitalization

$2.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

What Comes Next Could Be a Once-in-a-Lifetime Opportunity

From InvestorPlace | Ad

A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.

Click here now to watch the full briefing and discover the steps to take today.